Loading...
  • antibody response
  • A clinical vaccine efficacy study in mothers is currently underway to evaluate the effects on the antibody response (291). (damasgate.com)
  • Conventionally, vaccines are screened for induction of a neutralizing antibody response in human volunteers before proceeding to late-stage clinical trials. (pnas.org)
  • Our results suggest that more detailed laboratory studies are required to identify correlates of immune protection for such viruses and that failure of a vaccine to induce a neutralizing antibody response should not necessarily be considered as a key go-no-go decision point in the design of future vaccine studies. (pnas.org)
  • rotavirus vaccine
  • Among these is former Wistar researcher Stanley A. Plotkin, M.D., who during his career at the Institute between 1960 and 1991 developed the rubella vaccine that eradicated the disease in the U.S. and co-developed a new rotavirus vaccine approved in the U.S. in 2006. (rxpgnews.com)
  • Discoveries at Wistar have led to the creation of the rubella vaccine that eradicated the disease in the U.S., rabies vaccines used worldwide, and a new rotavirus vaccine approved in 2006. (rxpgnews.com)
  • Placebo
  • Study participants have been split into five groups that will receive three varying doses of VBI's adjuvanted vaccine candidate, an unadjuvanted version of the vaccine candidate, or a placebo control, at zero, two, and six months. (marketwired.com)
  • In each cohort, 14 subjects received a high, medium or low dose of the vaccine, respectively, and four received placebo. (sofinnova.fr)
  • Vaccine and placebo were administered on day zero, and one and three months after first injection. (sofinnova.fr)
  • Over all three dose groups, 98% of the subjects who received vaccine, and zero percent of the subjects who received placebo, showed detectable CMV-neutralizing antibody titers after three doses (93% of the subjects in the lowest dose group and 100% of the subjects in the medium and high dose groups). (sofinnova.fr)
  • Similarly, all three dose groups of the vaccine induced robust and statistically significant cellular immune responses when compared to placebo. (sofinnova.fr)
  • When looking specifically at pp65-specific CD8+ T cells, a key biomarker for cellular immunity against cytomegalovirus, the medium and high dose groups induced clinically and statistically significant responses when compared to placebo. (sofinnova.fr)
  • Seronegative animals were immunized with a two-dose series of each vaccine (0- and 3- week schedule), or placebo. (biomedcentral.com)
  • 2017
  • Vienna, Austria, 4 May 2017 - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today presented the un-blinded safety and immunogenicity data through month four from the Company's phase 1 first-in-human trial of HB-101, a vaccine against human cytomegalovirus (CMV), based on Hookipa's proprietary Vaxwave® platform. (sofinnova.fr)
  • vaccination
  • In the highest dose group, 100% seroconversion was already observed after the second vaccination and 79% of the subjects who received vaccine in this group, showed titers within the range of seropositive controls. (sofinnova.fr)
  • Markedly, the combination of SLP vaccines containing both MHC class I and II epitopes plus OX40 activation during booster vaccination resulted in polyfunctional (i.e. (frontiersin.org)
  • immunity
  • While safety and tolerability are our primary endpoints, we will also measure the immune response generated by our CMV vaccine candidate, and compare it to persons with naturally acquired CMV immunity. (marketwired.com)
  • A better understanding of the mechanisms of naturally acquired immunity to malaria may lead to insights for vaccine development. (jci.org)
  • Phase
  • The most advanced vaccine candidate, RTS,S, conferred partial protection against malaria in phase II clinical trials and is currently being evaluated in a phase III trial in Africa. (jci.org)
  • highest priority
  • Development of a CMV vaccine has been ranked as the highest priority by the Institute of Medicine, an independent agency of the National Academy of Science, because of "the lives it would save and the disabilities it would prevent," according to the CDC. (ucdavis.edu)
  • In 2000, the Institute of Medicine reported that a cytomegalovirus (CMV) vaccine had the highest priority based on cost savings ( 2 ). (asm.org)
  • study
  • It should be possible to develop a safe and effective CMV vaccine using the method we've described in our study. (rxpgnews.com)
  • Now, in a new study in the August 1 issue of The Journal of Virology, researchers at The Wistar Institute outline an innovative approach that could be used to create such a vaccine. (rxpgnews.com)
  • It should be possible to develop a safe and effective CMV vaccine using the method we've described in our study," says Gerd G. Maul, Ph.D., a professor in the Gene Expression and Regulation Program at Wistar and senior author on the new study. (rxpgnews.com)
  • Astellas and Vical employees, the investigators and study site personnel did an outstanding job conducting this study, but unfortunately, the vaccine was unable to provide protection against all-cause mortality in this very difficult-to-treat patient population. (globenewswire.com)
  • Another study evaluated the effect of CMV vaccine in prevent- ing child-to-mother transmission of CMV acquired in daycare centers (285). (damasgate.com)
  • Meghan K. Eberhardt, first author on the current CMV vaccine study. (ucdavis.edu)
  • We've completed the first step in developing a vaccine to protect people against CMV by interfering with the virus's attempts to enter and infect cells in the body," said Peter A. Barry , a professor of pathology and laboratory medicine at the UC Davis School of Medicine and lead author of the study. (ucdavis.edu)
  • Participants discussed optimal uses of a CMV vaccine, aspects of clinical study design, and the need for additional research in specified areas. (asm.org)
  • Other trials of different gB vaccines (GlaxoSmithKline and VBI) are also under way (registered at ClinicalTrials.gov under study numbers NCT00435396 and NCT02826798, respectively). (asm.org)
  • Cytomegalovirus Vaccine study RECRUITING NOW! (utmb.edu)
  • novel
  • In developing their novel vaccine strategy, the researchers focused on neutralizing CMV's own IL-10 so that the immune defense system was again capable of responding vigorously and effectively to the presence of the virus. (ucdavis.edu)
  • responses
  • METHODS: We evaluated the effect of age and CMV status on pneumococcal vaccine responses in 348 individuals aged 50-70 years. (ox.ac.uk)
  • MCMV
  • The objective of this project is to develop a more effective DNA vaccine against MCMV using pp89 in a plasmid containing lysosome-associated membrane protein (LAMP), which has been shown to enhance both cellular and humoral immune response with a variety of antigen and vector systems. (nus.edu.sg)